Chemomab (CMMB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$2.2M

Net income growth (year over year)

−5.25%

Net margin

—

Return on equity

−82.17%

EPS (trailing twelve months)

−$0.96

Book value per share

$1.20

P/E (trailing twelve months)

—

Price to book

1.20

Debt to assets

15.17%

Payout ratio

—

Dividend yield

—

Company profile

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

• How do I buy stock in Chemomab (CMMB)?

  CMMB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.